Minerva Neurosciences Inc
$ 6.25
-1.11%
24 Feb - close price
- Market Cap 26,924,600 USD
- Current Price $ 6.25
- High / Low $ 6.60 / 5.91
- Stock P/E N/A
- Book Value -4.95
- EPS -1.85
- Next Earning Report 2026-02-24
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -6.75 %
- 52 Week High 6.69
- 52 Week Low 1.15
About
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of candidate products for the treatment of diseases of the central nervous system. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$4.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-14 | 2025-05-13 | 2025-02-25 | 2024-11-05 | 2024-08-06 | 2024-05-01 | 2024-02-22 | 2023-11-07 | 2023-08-01 | 2023-05-15 | 2023-03-08 |
| Reported EPS | -0.36 | -0.43 | -0.5 | -0.56 | 2.97 | -1.09 | -1.13 | -1.39 | -1.03 | -1.12 | -1.31 | -1.26 |
| Estimated EPS | -0.35 | -0.9 | -1.07 | -1.05 | -1.01 | -0.97 | -1.2 | -0.88 | -0.77 | -0.44 | -1.63 | -0.92 |
| Surprise | -0.01 | 0.47 | 0.57 | 0.49 | 3.98 | -0.12 | 0.07 | -0.51 | -0.26 | -0.68 | 0.32 | -0.34 |
| Surprise Percentage | -2.8571% | 52.2222% | 53.271% | 46.6667% | 394.0594% | -12.3711% | 5.8333% | -57.9545% | -33.7662% | -154.5455% | 19.6319% | -36.9565% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-24 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.11 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NERV
2026-02-17 04:27:37
Minerva Neurosciences, Inc. (NASDAQ:NERV) recently saw its market cap reach US$271m, largely benefiting retail investors who hold 55% ownership, alongside institutional investors. The article details the ownership structure, noting that the top 25 shareholders own 45% and hedge funds hold 10%, indicating active investor interest. While retail investors have significant sway, the report also points out 5 warning signs for the company.
2026-02-16 14:58:00
Minerva Neurosciences, Inc.'s market capitalization reached US$271 million last week, positively impacting both its retail investors, who hold a 55% stake, and institutional investors, with a 21% ownership. Following an 11% increase in stock price, retail investors were the primary beneficiaries. Hedge funds and private equity firms also hold significant stakes in the company, at 10% each.
2026-02-07 06:57:57
Analysts are presenting conflicting sentiments for healthcare companies Minerva Neurosciences (NERV) and Verastem (VSTM). H.C. Wainwright initiated coverage on Verastem with a Buy rating and a price target of $18.00, contrasting with an overall "Strong Buy" consensus and a $15.50 average price target, implying a significant upside. No specific analyst ratings for Minerva Neurosciences are detailed in the provided content.
2026-02-06 08:57:53
Healthcare sector analysts have issued new ratings for Minerva Neurosciences (NERV) and Verastem (VSTM). H.C. Wainwright initiated coverage on Verastem with a Buy rating and an $18.00 price target, highlighting a strong consensus and significant upside potential for the stock.
2026-02-06 03:59:39
This article highlights analysts' conflicting sentiments on healthcare companies Minerva Neurosciences (NERV) and Verastem (VSTM). H.C. Wainwright initiated coverage on Verastem with a Buy rating and an $18.00 price target, while RBC Capital also maintained a Buy rating with a $15.00 price target, leading to a Strong Buy consensus for VSTM. The article does not provide specific analyst sentiment for Minerva Neurosciences.
2026-02-04 16:28:21
Minerva Neurosciences (NASDAQ: NERV) recently hosted a virtual event to discuss its drug candidate roluperidone, which targets negative symptoms in schizophrenia. The company unveiled its Confirmatory Phase 3 study design, featuring a 12-week double-blind monotherapy (Part A) followed by a relapse monitoring phase (Part B). Minerva anticipates the first patient in Q2 2026, with top-line 12-week results in H2 2027, aiming for an NDA resubmission with the FDA.
